<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article article-type="other" dtd-version="2.3" xml:lang="EN" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<?covid-19-tdm?>
<journal-meta>
<journal-id journal-id-type="publisher-id">Public Health Rev</journal-id>
<journal-title>Public Health Reviews</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Public Health Rev</abbrev-journal-title>
<issn pub-type="epub">2107-6952</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">1604269</article-id>
<article-id pub-id-type="doi">10.3389/phrs.2021.1604269</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Public Health Archive</subject>
<subj-group>
<subject>Policy Brief</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Easing Restrictions During Vaccine Scarcity. How Mitigation Measures Help Tackling Associated Moral and Behavioral Challenges</article-title>
<alt-title alt-title-type="left-running-head">Tretter et&#x20;al.</alt-title>
<alt-title alt-title-type="right-running-head">Easing Restrictions During Vaccine Scarcity</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Tretter</surname>
<given-names>Max</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1342380/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ehrlich</surname>
<given-names>David B.</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1422505/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>von Ulmenstein</surname>
<given-names>Ulrich</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1364802/overview"/>
</contrib>
</contrib-group>
<aff id="aff1">
<label>
<sup>1</sup>
</label>Department of Theology, University of Erlangen Nuremberg, <addr-line>Erlangen</addr-line>, <country>Germany</country>
</aff>
<aff id="aff2">
<label>
<sup>2</sup>
</label>Department of Economics and Management, Karlsruhe Institute of Technology (KIT), <addr-line>Karlsruhe</addr-line>, <country>Germany</country>
</aff>
<aff id="aff3">
<label>
<sup>3</sup>
</label>Department of Law, University of Giessen, <addr-line>Giessen</addr-line>, <country>Germany</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>
<bold>Edited by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1210350/overview">Sarah Mantwill</ext-link>, University of Lucerne, Switzerland</p>
</fn>
<fn fn-type="edited-by">
<p>
<bold>Reviewed by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1414847/overview">Nicola Diviani</ext-link>, Swiss Paraplegic Research, Switzerland</p>
</fn>
<corresp id="c001">&#x2a;Correspondence: Max Tretter, <email>max.tretter@fau.de</email>
</corresp>
</author-notes>
<pub-date pub-type="epub">
<day>21</day>
<month>10</month>
<year>2021</year>
</pub-date>
<pub-date pub-type="collection">
<year>2021</year>
</pub-date>
<volume>42</volume>
<elocation-id>1604269</elocation-id>
<history>
<date date-type="received">
<day>31</day>
<month>05</month>
<year>2021</year>
</date>
<date date-type="accepted">
<day>08</day>
<month>09</month>
<year>2021</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2021 Tretter, Ehrlich and von Ulmenstein.</copyright-statement>
<copyright-year>2021</copyright-year>
<copyright-holder>Tretter, Ehrlich and von Ulmenstein</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these&#x20;terms. PHR is edited by the Swiss School of Public Health (SSPH&#x002B;) in a partnership with the Association of Schools of Public Health of the European Region (ASPHER)&#x002B;
</p>
</license>
</permissions>
<abstract>
<p>
<bold>Background:</bold> When vaccines became first available during the Covid-19 pandemic, their demand significantly exceeded their supply. In consequence, the access to vaccines, initially, was distributed unequally. At the same time, governments started easing pandemic restrictions for vaccinated and recovered persons and restoring their freedoms since their risk of transmitting the virus is significantly reduced.</p>
<p>
<bold>Evidence:</bold> We show that restoring freedoms for vaccinated and recovered persons &#x2013; while upholding restrictions for the rest of the population &#x2013; is morally unfair during vaccine scarcity. Further, it may yield unintended side-effects, including perverse incentives, growing rifts in society, and the expansion of marginalization.</p>
<p>
<bold>Policy Options &#x26; Recommendations:</bold> We recommend accompanying easing for vaccinated and recovered individuals by mitigation measures for those who are neither vaccinated nor recovered. We propose, first, to temporarily lift the same restrictions for negative-tested individuals, as for vaccinated or recovered people. Second, the state must ensure broad and easy access to testing for everyone &#x2013; free of charge.</p>
<p>
<bold>Conclusion:</bold> If done right, these mitigation measures create (at least temporarily) equal access to freedom for everybody &#x2013; solving the moral problem of unfair access to freedoms and counteracting possible negative consequences.</p>
</abstract>
<kwd-group>
<kwd>COVID-19</kwd>
<kwd>mitigation measures</kwd>
<kwd>vaccination policy</kwd>
<kwd>Covid-19 protective measures exemption ordinance</kwd>
<kwd>Covid-19 restrictions</kwd>
<kwd>vaccination scarcity</kwd>
</kwd-group>
<contract-num rid="cn001">01GP1905A 01GP1905B 01GP1905C</contract-num>
<contract-sponsor id="cn001">Bundesministerium f&#xfc;r Bildung und Forschung<named-content content-type="fundref-id">10.13039/501100002347</named-content>
</contract-sponsor>
</article-meta>
</front>
<body>
<sec id="s1">
<title>Introduction</title>
<p>As pandemics emerge as a growing threat in the future, societies must be prepared to cope with recurring challenges. We focus on a challenge related to the phase in a pandemic when vaccines have become available, but the initially short supply cannot yet meet the vast demand, and not every willing person has had the chance to get inoculated yet. During this period, policymakers face special pressure to restore basic civil liberties for the immunized population while ensuring that the health care system will not be overburdened due to an overhasty return to normalcy and rapidly rising infection numbers. A common approach is to issue immunity certification to immunized individuals and ease their restrictions.</p>
<p>In our contribution, we examine how the unequal treatment of vaccinated and recovered individuals on the one hand, and the rest of the population on the other, is morally unfair and can produce unintended side effects. These effects include perverse incentives, growing rifts in society, and expanding marginalization. We claim that in order to prevent these negative consequences, it is crucial to introduce mitigation measures. By temporarily restoring the same freedoms for individuals who tested negative as for immunized individuals, these mitigation measures counteract inequalities in the population and thwart negative implications resulting from inequality.</p>
</sec>
<sec id="s2">
<title>Background</title>
<p>Public health policies face the challenge of, first, protecting national public health, second, enabling citizens to enjoy equitable freedoms [<xref ref-type="bibr" rid="B1">1</xref>]. The Covid-19 pandemic illustrates this challenge: In order to protect the health of their citizens, prevent them from infecting each other, and keep national health systems from being overburdened governments worldwide have to enact freedom-restricting public health policies [<xref ref-type="bibr" rid="B2">2</xref>]. This challenge continues until the first vaccines that could effectively prevent transmission were approved for general use and governments began vaccinating their citizens. This marks the entry of the pandemic into a new phase, during which vaccinations are still scarce and not everyone has had the opportunity to get vaccinated. We call it, referring to the WHO [<xref ref-type="bibr" rid="B3">3</xref>] a transition&#x20;phase.</p>
<p>This transition phase is of particular interest for the consideration of health care policy for several reasons. First, while high- and middle-income countries have already overcome this phase, there are still many countries in the midst of it [<xref ref-type="bibr" rid="B4">4</xref>]. And despite all efforts to achieve global immunization equity (COVAX), some models show that especially poorer countries will have to wait a long time for sufficient vaccination coverage [<xref ref-type="bibr" rid="B4">4</xref>, <xref ref-type="bibr" rid="B5">5</xref>]. Second, there is a risk that the emergence of new virus variants could render current vaccines ineffective or drastically reduce their effectiveness [<xref ref-type="bibr" rid="B6">6</xref>], so that new vaccines would be needed&#x2014;which would set the Covid-19 pandemic back to the stage of a global vaccine scarcity. Third, this transitional phase of vaccine scarcity can be viewed as a typical part of a pandemic. Given the prediction that pandemics may become more frequent in the future [<xref ref-type="bibr" rid="B7">7</xref>], fundamental considerations about policy options during this phase are important.</p>
<p>During this transitional phase and due to the perceived safety of vaccination many governments are considering to or are already easing the restrictions for vaccinated as well as for recovered individuals [<xref ref-type="bibr" rid="B8">8</xref>, <xref ref-type="bibr" rid="B9">9</xref>] &#x2013; often introducing immunity certificates for this purpose [<xref ref-type="bibr" rid="B10">10</xref>]. Justifications for facilitating vaccinated and recovered individuals are often based on the principle of proportionality of policy measures [<xref ref-type="bibr" rid="B11">11</xref>, <xref ref-type="bibr" rid="B12">12</xref>]. The existing restrictions are intended to prevent individuals from transmitting Covid-19 and spreading the infection &#x2013; and can be considered, legally, morally, and medically suitable, as long as they affect individuals who are able to transmit Covid-19. Further, vaccination against and recent recovery from Covid-19 significantly lower the probability to infect others [<xref ref-type="bibr" rid="B13">13</xref>] &#x2013; especially if the basic preventive measures of wearing a medical mask in public and maintaining physical distance remain in place. Therefore, the restrictions no longer fulfill their initial purpose for vaccinated and recovered individuals &#x2013; which makes easing their restrictions a mandatory consequence.</p>
</sec>
<sec id="s3">
<title>Evidence</title>
<p>We apply a moral and subsequently a behavioral point of view to raise objections and illustrate problems in conjunction with easing restrictions for vaccinated and recently recovered individuals.</p>
<p>From a moral perspective, introducing easings for vaccinated and recovered persons is unjust when vaccine scarcity exists. The distribution of a good is only just if all persons have equal and fair access to it [<xref ref-type="bibr" rid="B14">14</xref>]. But as long as vaccine scarcity limits the number of people who can get vaccinated, there will be an unequal distribution of vaccinations, and some will have to wait longer than others. Where this unequal distribution follows vaccine prioritization, for which there are good reasons &#x2013; e.g., higher risk of severe courses of Covid-19, higher exposure risks to the virus, or higher likelihood of transmission [<xref ref-type="bibr" rid="B15">15</xref>] &#x2013;, and which follows moral values [<xref ref-type="bibr" rid="B16">16</xref>] it is fair and morally legitimate. However, where the restrictions are additionally eased for vaccinated as well as for recovered individuals it is no longer fair [<xref ref-type="bibr" rid="B17">17</xref>]. Instead, this would be tantamount to illegitimately withholding freedoms from people who want to get vaccinated but can&#x2019;t &#x2013; which would be unfair and also place an enormous burden on them [<xref ref-type="bibr" rid="B11">11</xref>]. This moral problem of unfair access to scarce vaccinations and subsequent easing of restrictions is further exacerbated when there are no good reasons for the intra-societally or globally unequal distribution of vaccines [<xref ref-type="bibr" rid="B4">4</xref>,&#x20;<xref ref-type="bibr" rid="B17">17</xref>].</p>
<p>A focal point in the behavioral framework of analyzing any public policy proposal is the assessment of potential side effects and unintended consequences. Even a well-meaning and mandatory policy can produce results contrary to its designated end. With regard to easing restrictions for vaccinated and recovered individuals, we raise several concerns that should be duly reflected in the further discourse. They are largely based on the fact that the vaccines are initially rare goods when they are newly introduced, and demand typically exceeds the short supply.</p>
<p>Regarding societal support for the idea of easing restrictions for the immunized population, the empirical evidence is still limited [<xref ref-type="bibr" rid="B9">9</xref>]. However, public and scientific opinion seems to be far from a consensus [<xref ref-type="bibr" rid="B8">8</xref>, <xref ref-type="bibr" rid="B18">18</xref>]. According to some estimates, the part of the population opposing immunity certification &#x2013; the common policy approach toward easings for vaccinated and recovered individuals [<xref ref-type="bibr" rid="B10">10</xref>] &#x2013; might be nearly as large as the supporting part [<xref ref-type="bibr" rid="B9">9</xref>, <xref ref-type="bibr" rid="B19">19</xref>]. A substantial amount of people appear concerned by the potential for discrimination [<xref ref-type="bibr" rid="B20">20</xref>] and the potential &#x201c;harm [to] the social fabric of their community&#x201d; [<xref ref-type="bibr" rid="B19">19</xref>]. These perceptions align with empirical evidence from economic experiments where we see that people are generally averse to inequity &#x2013; and are even willing to destroy their own payoffs &#x2013; when it exceeds a certain threshold&#x20;[<xref ref-type="bibr" rid="B21">21</xref>].</p>
<p>We share the concern that &#x2013; on a collective level &#x2013; the introduction of easings based on immunization threatens to produce a growing rift in society between the vaccinated and recovered on the one side and the rest of the population on the other. As is evident by now, the risk associated with a Covid-19 infection is already linked to socioeconomic factors. Individuals with lower income and education levels are at higher risk of contracting Covid-19 [<xref ref-type="bibr" rid="B22">22</xref>] and suffering from a severe course of disease or death [<xref ref-type="bibr" rid="B23">23</xref>]. Even with the financial cost of vaccinations borne by the state, individual access to vaccines is, again, related to socioeconomic status [<xref ref-type="bibr" rid="B24">24</xref>], e.g., through differences in technological skills, internet access, personal networks, mistrust of the health care system, and susceptibility to misinformation [<xref ref-type="bibr" rid="B25">25</xref>]. Therefore, easing restrictions for the vaccinated could contribute to reinforcing pre-existent inequalities [<xref ref-type="bibr" rid="B26">26</xref>, <xref ref-type="bibr" rid="B27">27</xref>], resulting in persons with higher income and better education facing lower medical risks and enjoying more freedoms. This problem exacerbates whenever immunization is required to access specific jobs [<xref ref-type="bibr" rid="B26">26</xref>], e.g., in care work or hospitality. In such cases, not only are pre-existing inequalities reinforced, but there is a threat of marginalization &#x2013; of individuals being excluded from public, social, and working&#x20;life.</p>
<p>Besides these implications, there are more practical challenges as well, such as the potential for fraudulent behavior [<xref ref-type="bibr" rid="B28">28</xref>] and the creation of <italic>perverse incentives</italic> for those who think themselves at very low risk for a severe course of the disease [<xref ref-type="bibr" rid="B26">26</xref>] to get infected on purpose to circumvent restrictions.</p>
<p>However, easing restrictions for vaccinated and recovered people holds vast benefits promising to clearly outweigh the concerns mentioned above. First, it generates a solid incentive to get vaccinated [<xref ref-type="bibr" rid="B29">29</xref>]. This incentive is especially relevant when considering a long-term perspective that incorporates subsequent phases of trying to emerge from the pandemic [<xref ref-type="bibr" rid="B30">30</xref>]. Besides restoring civil liberties, there are economic and mental health benefits when everyday life is gradually resumed, and restrictions vanish.</p>
<p>Both positive and negative implications cannot and should not be ignored. The scope and concrete implementation of easing restrictions &#x2013; with a particular focus how to approach inequality in the process &#x2013; will be the primary factor determining whether positive or negative effects dominate. A considerate design of mitigation measures &#x2013; intended to reduce inequalities &#x2013; can reduce the risk of undesired behavioral and societal side-effects.</p>
</sec>
<sec id="s4">
<title>Policy Options and Recommendations</title>
<p>The transitional phase with scarce vaccines poses a challenge to public health policy: On the one hand, it is mandatory to ease the restrictions of vaccinated and recovered individuals. On the other hand, easing their restrictions is morally unfair and illegitimate and could lead to adverse behavioral implications. Nonetheless, it would be irresponsible to ease restrictions indiscriminately for all persons, regardless of whether they are vaccinated, recovered, tested, or neither, as this would risk an enormous increase in infection rates and might overburden the healthcare system [<xref ref-type="bibr" rid="B6">6</xref>]. Considering this situation, we propose a tiered approach with easings for vaccinated and recovered individuals and mitigating measures for non-vaccinated or non-recovered individuals during this transition phase &#x2013; for which we draw inspiration from measures implemented in Germany.</p>
<p>When Germany was in an analogous transitional phase and at the same time recorded high infection rates, it introduced two policy measures. First, the so-called federal emergency brake [<xref ref-type="bibr" rid="B31">31</xref>] imposed contact restrictions and a curfew on all citizens and prohibited retail shopping and the use of personal services. Second, the <italic>Covid-19 Protective Measures Exemption Ordinance</italic> introduced easings for vaccinated and recovered citizens who were henceforth exempt from the above restrictions [<xref ref-type="bibr" rid="B32">32</xref>]. In addition, non-vaccinated and non-recovered persons had the opportunity to regain some freedoms temporarily: When showing a negative test that was no older than 24&#xa0;h, people could, for example, shop at retail stores and access medical and related services while their contact restrictions and curfews remained in place&#x20;[<xref ref-type="bibr" rid="B31">31</xref>].</p>
<p>With these policy measures, the German government was able to offer its citizens (at least temporary) freedoms while at the same time protecting national public health. However, although there was still a vaccine shortage, the policy measure granted more easings to vaccinated and recovered persons than negative-tested &#x2013; creating unfair access to freedoms, thus losing its moral legitimacy and risking negative behavioral implications.</p>
<p>We propose to adopt the German approach in large parts but to adapt it so that negative-tested individuals temporarily have the same freedoms as vaccinated or recovered people. This includes lifting their contact restrictions and curfews for the 24&#xa0;h following the test. To ensure that this mitigation measure is effective and does not create additional burdens for people in need [<xref ref-type="bibr" rid="B29">29</xref>], e.g., by requiring them to travel long distances, wait a long time, or pay a lot of money, we propose that sufficient testing capacities must be accessible all weekdays during daytime and in accessible proximity, and the cost of testing must be shared equitably between everybody [<xref ref-type="bibr" rid="B27">27</xref>,&#x20;<xref ref-type="bibr" rid="B33">33</xref>].</p>
<p>When implemented, these mitigation measures create equal opportunities for everybody to have their restrictions at least temporarily eased &#x2013; solving the moral problem of unfair access to freedoms. On a behavioral level, these mitigation measures counteract the perverse incentives that arise from unequal access to freedom [<xref ref-type="bibr" rid="B27">27</xref>, <xref ref-type="bibr" rid="B29">29</xref>]. In addition, they help to prevent tensions in society, as all individuals have the opportunity to enjoy the same freedoms [<xref ref-type="bibr" rid="B34">34</xref>] &#x2013; and ensuring the wide accessibility of these tests without additional burdens contributes to preventing the expansion of social marginalization [<xref ref-type="bibr" rid="B33">33</xref>]. Mitigation measures could also convince the opposing part of the population [<xref ref-type="bibr" rid="B9">9</xref>, <xref ref-type="bibr" rid="B19">19</xref>] of easings for vaccinated and recovered individuals &#x2013; by addressing and resolving their concerns about potential discrimination [<xref ref-type="bibr" rid="B20">20</xref>] and harm to the community&#x20;[<xref ref-type="bibr" rid="B19">19</xref>].</p>
<p>On the contrary, implementing these mitigation measures can lead to two problems: First, due to the accuracy of tests [<xref ref-type="bibr" rid="B34">34</xref>], negative-tested individuals are assumed to have a higher residual risk of transmitting Covid-19 than vaccinated and recovered individuals. Second, they could increase existing vaccine hesitancy [<xref ref-type="bibr" rid="B35">35</xref>]. However, first, as the remaining residual risks are not sufficient to justify the maintenance of restrictions for vaccinated and recovered individuals, it would be inconsistent to use them as an argument against temporarily restoring equal freedoms to negative-tested individuals. Plus, if tests are performed regularly and in clusters, their false-negative rate is significantly lower [<xref ref-type="bibr" rid="B34">34</xref>]. Second, vaccine hesitancy is not a problem during vaccine scarcity because the demand for vaccines always exceeds their supply in the transitional phase. These mitigation measures must be adjusted as soon as sufficient vaccines are available.</p>
</sec>
<sec sec-type="conclusion" id="s5">
<title>Conclusion</title>
<p>As long as there is a scarcity of vaccines, it is morally unfair to ease restrictions for vaccinated and recovered individuals without providing opportunities for the rest of the population to regain the same freedoms temporarily. Furthermore, doing so can yield unintended behavioral side-effects. Concerns include perverse incentives, growing rifts in society, and the expansion of marginalization. To address these problems and to counteract the injustice without withdrawing previous easings, we propose the following: First, the same restrictions must be lifted for negative-tested individuals as for vaccinated or recovered people &#x2013; so that the former have the opportunity to temporarily regain the same freedoms that the latter regain permanently. Second, the government must ensure extensive and easy access to testing for everyone &#x2013; free of charge.</p>
</sec>
</body>
<back>
<sec id="s6">
<title>Author Contributions</title>
<p>MT, DE, and UVU all contributed to the final paper through conceptualizing, writing, and editing.</p>
</sec>
<sec id="s7">
<title>Funding</title>
<p>This work has been funded by grants from the Federal Ministry of Research and Education (grant numbers: 01GP1905A, 01GP1905B, and 01GP1905C).</p>
</sec>
<sec sec-type="COI-statement" id="s8">
<title>Conflict of Interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<label>1.</label>
<citation citation-type="book">
<person-group person-group-type="editor">
<name>
<surname>Dawson</surname>
<given-names>A</given-names>
</name>
</person-group>, eds. <source>Public Health Ethics. Key Concepts and Issues in Policy and Practice</source>. <publisher-loc>Cambridge, New York</publisher-loc>: <publisher-name>Cambridge University Press</publisher-name> (<year>2011</year>). </citation>
</ref>
<ref id="B2">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gostin</surname>
<given-names>LO</given-names>
</name>
<name>
<surname>Wiley</surname>
<given-names>LF</given-names>
</name>
</person-group>. <article-title>Governmental Public Health Powers During the COVID-19 Pandemic</article-title>. <source>JAMA</source> (<year>2020</year>). <volume>323</volume>(<issue>21</issue>):<fpage>2137</fpage>&#x2013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1001/jama.2020.5460</pub-id> </citation>
</ref>
<ref id="B3">
<label>3.</label>
<citation citation-type="book">
<collab>World Health Organization</collab>. <source>Strengthening and Adjusting Public Health Measures throughout the COVID-19 Transition Phases</source>. <comment>Policy considerations for the WHO European Region</comment>. <publisher-loc>Copenhagen</publisher-loc>: <publisher-name>World Health Organization</publisher-name> (<year>2020</year>). </citation>
</ref>
<ref id="B4">
<label>4.</label>
<citation citation-type="book">
<collab>Our World In Data</collab>. <source>Coronavirus (COVID-19) Vaccinations</source> (<year>2021</year>). <comment>Available from: <ext-link ext-link-type="uri" xlink:href="https://ourworldindata.org/covid-vaccinations">https://ourworldindata.org/covid-vaccinations</ext-link> (cited 08&#x20;03, 2021)</comment>. </citation>
</ref>
<ref id="B5">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Padma</surname>
<given-names>TV</given-names>
</name>
</person-group>. <article-title>COVID Vaccines to Reach Poorest Countries in 2023&#x20;- Despite Recent Pledges</article-title>. <source>Nature</source> (<year>2021</year>). <volume>595</volume>(<issue>7867</issue>):<fpage>342</fpage>&#x2013;<lpage>3</lpage>. <pub-id pub-id-type="doi">10.1038/d41586-021-01762-w</pub-id> </citation>
</ref>
<ref id="B6">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Iftekhar</surname>
<given-names>EN</given-names>
</name>
<name>
<surname>Priesemann</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Balling</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Bauer</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Beutels</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Calero Valdez</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group> <article-title>A Look into the Future of the COVID-19 Pandemic in Europe: An Expert Consultation</article-title>. <source>The Lancet Reg Health - Europe</source> (<year>2021</year>). <volume>8</volume>:<fpage>100185</fpage>. <pub-id pub-id-type="doi">10.1016/j.lanepe.2021.100185</pub-id> </citation>
</ref>
<ref id="B7">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tollefson</surname>
<given-names>J</given-names>
</name>
</person-group>. <article-title>Why Deforestation and Extinctions Make Pandemics More Likely</article-title>. <source>Nature</source> (<year>2020</year>). <volume>584</volume>(<issue>7820</issue>):<fpage>175</fpage>&#x2013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1038/d41586-020-02341-1</pub-id> </citation>
</ref>
<ref id="B8">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aranzales</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Chan</surname>
<given-names>HF</given-names>
</name>
<name>
<surname>Eichenberger</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Hegselmann</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Stadelmann</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Torgler</surname>
<given-names>B</given-names>
</name>
</person-group>. <article-title>Scientists Have Favorable Opinions on Immunity Certificates but Raise Concerns Regarding Fairness and Inequality</article-title>. <source>Sci Rep</source> (<year>2021</year>). <volume>11</volume>(<issue>1</issue>):<fpage>14016</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-021-93148-1</pub-id> </citation>
</ref>
<ref id="B9">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Drury</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Mao</surname>
<given-names>G</given-names>
</name>
<name>
<surname>John</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kamal</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Rubin</surname>
<given-names>GJ</given-names>
</name>
<name>
<surname>Stott</surname>
<given-names>C</given-names>
</name>
<etal/>
</person-group> <article-title>Behavioural Responses to Covid-19 Health Certification: A Rapid Review</article-title>. <source>BMC Public Health</source> (<year>2021</year>). <volume>21</volume>:<fpage>1205</fpage>. <comment>medRxiv</comment>. <pub-id pub-id-type="doi">10.1186/s12889-021-11166-0</pub-id> </citation>
</ref>
<ref id="B10">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brown</surname>
<given-names>RCH</given-names>
</name>
<name>
<surname>Savulescu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Williams</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Wilkinson</surname>
<given-names>D</given-names>
</name>
</person-group>. <article-title>Passport to freedom? Immunity Passports for COVID-19</article-title>. <source>J&#x20;Med Ethics</source> (<year>2020</year>). <volume>46</volume>(<issue>10</issue>):<fpage>652</fpage>&#x2013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1136/medethics-2020-106365</pub-id> </citation>
</ref>
<ref id="B11">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Paris</surname>
<given-names>E</given-names>
</name>
</person-group>, <article-title>Applying the Proportionality Principle to COVID-19 Certificates</article-title>
<italic>.</italic> <source>Eur J&#x20;Risk Regul</source>. (<year>2021</year>). <volume>12</volume>:<fpage>1</fpage>&#x2013;<lpage>11</lpage>. <pub-id pub-id-type="doi">10.1017/err.2021.27</pub-id> </citation>
</ref>
<ref id="B12">
<label>12.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Schmitz</surname>
<given-names>T</given-names>
</name>
</person-group>. <article-title>COVID-19 Response and Human Rights - Comments from the German and European Perspective</article-title>. In: <source>Advances in Social Science</source>. <publisher-loc>Dordrecht</publisher-loc>: <publisher-name>Atlantis Press</publisher-name> (<year>2020</year>). <pub-id pub-id-type="doi">10.2991/assehr.k.201209.357</pub-id> </citation>
</ref>
<ref id="B13">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dan</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Mateus</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Kato</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Hastie</surname>
<given-names>KM</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>ED</given-names>
</name>
<name>
<surname>Faliti</surname>
<given-names>CE</given-names>
</name>
<etal/>
</person-group> <article-title>Immunological Memory to SARS-CoV-2 Assessed for up to 8&#x20;Months after Infection</article-title>. <source>Science</source> (<year>2021</year>). <volume>371</volume>(<issue>6529</issue>):<fpage>371</fpage>. <pub-id pub-id-type="doi">10.1126/science.abf4063</pub-id> </citation>
</ref>
<ref id="B14">
<label>14.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Rawls</surname>
<given-names>J</given-names>
</name>
</person-group>. <source>Justice as Fairness: A Restatement</source>. <publisher-loc>Cambridge, London</publisher-loc>: <publisher-name>Harvard University Press</publisher-name> (<year>2001</year>). </citation>
</ref>
<ref id="B15">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Giubilini</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Savulescu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Wilkinson</surname>
<given-names>D</given-names>
</name>
</person-group>. <article-title>Queue Questions: Ethics of COVID&#x2010;19 Vaccine Prioritization</article-title>. <source>Bioethics</source> (<year>2021</year>). <volume>35</volume>(<issue>4</issue>):<fpage>348</fpage>&#x2013;<lpage>55</lpage>. <pub-id pub-id-type="doi">10.1111/bioe.12858</pub-id> </citation>
</ref>
<ref id="B16">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Persad</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Peek</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Emanuel</surname>
<given-names>EJ</given-names>
</name>
</person-group>. <article-title>Fairly Prioritizing Groups for Access to COVID-19 Vaccines</article-title>. <source>JAMA</source> (<year>2020</year>). <volume>324</volume>(<issue>16</issue>):<fpage>1601</fpage>&#x2013;<lpage>2</lpage>. <pub-id pub-id-type="doi">10.1001/jama.2020.18513</pub-id> </citation>
</ref>
<ref id="B17">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kosciejew</surname>
<given-names>MRH</given-names>
</name>
</person-group>. <article-title>COVID-19 Immunity (Or Vaccine) Passports: A Documentary Overview and Analysis of Regimes of Health Verification within the Coronavirus Pandemic</article-title>. <source>J&#x20;Documentation</source> (<year>2021</year>). <comment>
<bold>ahead-of-print</bold>(ahead-of-print)</comment>. <pub-id pub-id-type="doi">10.1108/jd-04-2021-0079</pub-id> </citation>
</ref>
<ref id="B18">
<label>18.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lewandowsky</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Dennis</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Perfors</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kashima</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>White</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Garrett</surname>
<given-names>P</given-names>
</name>
<etal/>
</person-group> <article-title>Public Acceptance of Privacy-Encroaching Policies to Address the COVID-19 Pandemic in the United&#x20;Kingdom</article-title>. <source>PLoS One</source> (<year>2021</year>). <volume>16</volume>(<issue>1</issue>):<fpage>e0245740</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0245740</pub-id> </citation>
</ref>
<ref id="B19">
<label>19.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hall</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Studdert</surname>
<given-names>DM</given-names>
</name>
</person-group>. <article-title>Public Views about COVID-19 &#x2bd;Immunity Passports&#x27;</article-title>. <source>J&#x20;L Biosci</source> (<year>2021</year>). <volume>8</volume>(<issue>1</issue>):<fpage>lsab016</fpage>. <pub-id pub-id-type="doi">10.1093/jlb/lsab016</pub-id> </citation>
</ref>
<ref id="B20">
<label>20.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nehme</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Stringhini</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Guessous</surname>
<given-names>I</given-names>
</name>
</person-group>
<collab>SEROCoV-Pop Study Team</collab>. <article-title>Perceptions of Immunity and Vaccination Certificates Among the General Population: A Nested Study within a Serosurvey of Anti-SARS-CoV-2 Antibodies (SEROCoV-POP)</article-title>. <source>Swiss Med Wkly</source> (<year>2020</year>). <volume>150</volume>:<fpage>w20398</fpage>. <pub-id pub-id-type="doi">10.4414/smw.2020.20398</pub-id> </citation>
</ref>
<ref id="B21">
<label>21.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fehr</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Schmidt</surname>
<given-names>KM</given-names>
</name>
</person-group>. <article-title>A Theory of Fairness, Competition, and Cooperation</article-title>. <source>Q J&#x20;Econ</source> (<year>1999</year>). <volume>114</volume>(<issue>3</issue>):<fpage>817</fpage>&#x2013;<lpage>68</lpage>. <pub-id pub-id-type="doi">10.1162/003355399556151</pub-id> </citation>
</ref>
<ref id="B22">
<label>22.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Oh</surname>
<given-names>TK</given-names>
</name>
<name>
<surname>Choi</surname>
<given-names>J-W</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>I-A</given-names>
</name>
</person-group>. <article-title>Socioeconomic Disparity and the Risk of Contracting COVID-19 in South Korea: An NHIS-COVID-19 Database Cohort Study</article-title>. <source>BMC Public Health</source> (<year>2021</year>). <volume>21</volume>(<issue>1</issue>):<fpage>144</fpage>. <pub-id pub-id-type="doi">10.1186/s12889-021-10207-y</pub-id> </citation>
</ref>
<ref id="B23">
<label>23.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mena</surname>
<given-names>GE</given-names>
</name>
<name>
<surname>Martinez</surname>
<given-names>PP</given-names>
</name>
<name>
<surname>Mahmud</surname>
<given-names>AS</given-names>
</name>
<name>
<surname>Marquet</surname>
<given-names>PA</given-names>
</name>
<name>
<surname>Buckee</surname>
<given-names>CO</given-names>
</name>
<name>
<surname>Santillana</surname>
<given-names>M</given-names>
</name>
</person-group>. <article-title>Socioeconomic Status Determines COVID-19 Incidence and Related Mortality in Santiago, Chile</article-title>. <source>Science</source> (<year>2021</year>). <volume>372</volume>:<fpage>eabg5298</fpage>. <pub-id pub-id-type="doi">10.1126/science.abg5298</pub-id> </citation>
</ref>
<ref id="B24">
<label>24.</label>
<citation citation-type="book">
<collab>CDC. COVID</collab>. <source>Data Tracker. Health Equity Data</source> (<year>2021</year>). <comment>Available from: <ext-link ext-link-type="uri" xlink:href="https://covid.cdc.gov/covid-data-tracker/#health-equity-data">https://covid.cdc.gov/covid-data-tracker/&#x23;health-equity-data</ext-link> (cited 08&#x20;13, 2021)</comment>. </citation>
</ref>
<ref id="B25">
<label>25.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Solaiman</surname>
<given-names>RH</given-names>
</name>
<name>
<surname>Marette</surname>
<given-names>S</given-names>
</name>
</person-group>. <article-title>COVID-19 Vaccination Inequity in the United&#x20;States: An Intersectional Issue</article-title>. <source>J&#x20;Health Soc Sci</source> (<year>2021</year>). <volume>6</volume>(<issue>2</issue>):<fpage>167</fpage>&#x2013;<lpage>74</lpage>. </citation>
</ref>
<ref id="B26">
<label>26.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kofler</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Baylis</surname>
<given-names>F</given-names>
</name>
</person-group>. <article-title>Ten Reasons Why Immunity Passports Are a Bad Idea</article-title>. <source>Nature</source> (<year>2020</year>). <volume>581</volume>(<issue>7809</issue>):<fpage>379</fpage>&#x2013;<lpage>81</lpage>. <pub-id pub-id-type="doi">10.1038/d41586-020-01451-0</pub-id> </citation>
</ref>
<ref id="B27">
<label>27.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Voo</surname>
<given-names>TC</given-names>
</name>
<name>
<surname>Reis</surname>
<given-names>AA</given-names>
</name>
<name>
<surname>Thom&#xe9;</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Ho</surname>
<given-names>CW</given-names>
</name>
<name>
<surname>Tam</surname>
<given-names>CC</given-names>
</name>
<name>
<surname>Kelly-Cirino</surname>
<given-names>C</given-names>
</name>
<etal/>
</person-group> <article-title>Immunity Certification for COVID-19: Ethical Considerations</article-title>. <source>Bull World Health Organ</source> (<year>2021</year>). <volume>99</volume>:<fpage>155</fpage>&#x2013;<lpage>61</lpage>. <pub-id pub-id-type="doi">10.2471/blt.20.280701</pub-id> </citation>
</ref>
<ref id="B28">
<label>28.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hall</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Studdert</surname>
<given-names>DM</given-names>
</name>
</person-group>. <article-title>Privileges and Immunity Certification During the COVID-19 Pandemic</article-title>. <source>JAMA</source> (<year>2020</year>). <volume>323</volume>(<issue>22</issue>):<fpage>2243</fpage>&#x2013;<lpage>4</lpage>. <pub-id pub-id-type="doi">10.1001/jama.2020.7712</pub-id> </citation>
</ref>
<ref id="B29">
<label>29.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Phelan</surname>
<given-names>AL</given-names>
</name>
</person-group>. <article-title>COVID-19 Immunity Passports and Vaccination Certificates: Scientific, Equitable, and Legal Challenges</article-title>. <source>The Lancet</source> (<year>2020</year>). <volume>395</volume>(<issue>10237</issue>):<fpage>1595</fpage>&#x2013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/s0140-6736(20)31034-5</pub-id> </citation>
</ref>
<ref id="B30">
<label>30.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Serra-Garcia</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Szech</surname>
<given-names>N</given-names>
</name>
</person-group>. <source>Choice Architecture and Incentives Increase COVID-19 Vaccine Intentions and Test Demand</source>. <publisher-name>SSRN</publisher-name> (<year>2021</year>). </citation>
</ref>
<ref id="B31">
<label>31.</label>
<citation citation-type="book">
<collab>The Federal Government of Germany</collab>. <source>Nationwide Emergency Brake Passed</source>. <comment>The Federal Government</comment> (<year>2021</year>). <comment>Available from: <ext-link ext-link-type="uri" xlink:href="https://www.bundesregierung.de/breg-en/news/nationwide-emergency-brake-1889136">https://www.bundesregierung.de/breg-en/news/nationwide-emergency-brake-1889136</ext-link> (Accessed 04&#x20;21, 2021)</comment>. </citation>
</ref>
<ref id="B32">
<label>32.</label>
<citation citation-type="book">
<collab>The Federal Government of Germany</collab>. <source>Restrictions Eased for Those Who Are Vaccinated or Have Recovered from COVID-19</source>. <comment>The Federal Government</comment> (<year>2021</year>). <comment>Available from: <ext-link ext-link-type="uri" xlink:href="https://www.bundesregierung.de/breg-en/news/easing-restrictions-for-vaccinated-1911192">https://www.bundesregierung.de/breg-en/news/easing-restrictions-for-vaccinated-1911192</ext-link> (Accessed 05&#x20;05, 2021)</comment>. </citation>
</ref>
<ref id="B33">
<label>33.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gerke</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Katznelson</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Reiss</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Shachar</surname>
<given-names>C</given-names>
</name>
</person-group>. <article-title>COVID-19 Antibody Testing as a Precondition for Employment: Ethical and Legal Considerations</article-title>. <source>J&#x20;L Med. Ethics</source> (<year>2021</year>). <volume>49</volume>(<issue>2</issue>):<fpage>293</fpage>&#x2013;<lpage>302</lpage>. <pub-id pub-id-type="doi">10.1017/jme.2021.42</pub-id> </citation>
</ref>
<ref id="B34">
<label>34.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Crozier</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Rajan</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Buchan</surname>
<given-names>I</given-names>
</name>
<name>
<surname>McKee</surname>
<given-names>M</given-names>
</name>
</person-group>. <article-title>Put to the Test: Use of Rapid Testing Technologies for Covid-19</article-title>. <source>BMJ</source> (<year>2021</year>). <volume>372</volume>:<fpage>n208</fpage>. <pub-id pub-id-type="doi">10.1136/bmj.n208</pub-id> </citation>
</ref>
<ref id="B35">
<label>35.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Troiano</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Nardi</surname>
<given-names>A</given-names>
</name>
</person-group>. <article-title>Vaccine Hesitancy in the Era of COVID-19</article-title>. <source>Public Health</source> (<year>2021</year>). <volume>194</volume>:<fpage>245</fpage>&#x2013;<lpage>51</lpage>. <pub-id pub-id-type="doi">10.1016/j.puhe.2021.02.025</pub-id> </citation>
</ref>
</ref-list>
</back>
</article>